- Raised $1.5M funding round, Feb 2008
- Raised $1M funding round, Jan 2002
- Raised $1.5M grant
About
Optimata uses high-level, multiscale modeling that integrates rational analysis of treatment mechanisms with information from large databases to develop solutions for predicting an oncology patients prognosis and the benefit they may gain from drug therapy, thus enabling improved treatment decisions. Optimatas PrediCare is a decision support tool that aims to help oncologists select the optimal therapy program. PrediCare uses the cancer patients individual clinical attributes (e.g. historic disease profile, biomarkers, etc.) to predict their response to different regimens and help identify the most appropriate treatment. The companys Virtual Patient platform, OVP, tailors drug regimens to patient populations and subpopulations. It is based on a system of mathematical models describing pathological, physiological, and pharmacological processes on multiple scales and adjusted to reflect the populations dynamics. The interactive models can be used to simulate different treatment protocols and optimize treatment schedules for a given patient population based on criteria defined by the user. The OVP platform has already undergone a proof-of-concept in breast cancer patients and in drug development, and has been adopted by biotech and pharmaceutical companies worldwide.
Funding history · 3 rounds · $4.0M total
Q&A
- What is Optimata's primary focus?
- Optimata focuses on personalized oncology treatment, using multiscale modeling to predict patient prognosis and the benefit from drug therapy, aiming to improve treatment decisions.
- What is PrediCare?
- PrediCare is Optimata's decision support tool designed to help oncologists select optimal therapy programs by predicting patient response to different regimens based on individual clinical attributes.
- What is the Virtual Patient platform (OVP)?
- Optimata's Virtual Patient platform (OVP) tailors drug regimens to patient populations and subpopulations using mathematical models to simulate treatment protocols and optimize schedules.
- Has the OVP platform been validated?
- The OVP platform has undergone a proof-of-concept in breast cancer patients and in drug development, and has been adopted by biotech and pharmaceutical companies worldwide.
- When was Optimata founded?
- Optimata was founded in January 2000.
- What is Optimata's current status?
- Optimata is currently inactive, having ceased operations in December 2021.
- What was Optimata's total funding raised?
- Optimata raised a total of $4,000,000 USD.
- When was Optimata's last funding round and who participated?
- Optimata's last funding round was in February 2008, with participation from Trimaran Capital Partners.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/84422 |
Identifiers & details
| Founded | 2000-1 |
|---|---|
| Employees (exact) | 9 |
| Status reason | Non Active, Dec 2021 ceased to operate |